{
    "clinical_study": {
        "@rank": "127945", 
        "arm_group": [
            {
                "arm_group_label": "Ustekinumab 90 mg/mL", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Ustekinumab 5 mg/mL", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetic (PK) (blood levels)\n      comparability of 2 different formulations of ustekinumab, 90 milligram per milliliter\n      (mg/mL) liquid in vial (LIV) and 5 mg/mL LIV, following a single intravenous administration\n      of 6 milligram per kilogram (mg/kg) ustekinumab, diluted in saline, in healthy participants."
        }, 
        "brief_title": "A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a multicenter (when more than one hospital or medical school team work on a medical\n      research study), randomized (study drug is assigned by chance), parallel (a clinical trial\n      comparing the response in two or more groups of participants receiving different\n      treatments), open-label (all people know the identity of the intervention) single-dose,\n      inpatient/outpatient study in healthy participants. The study consists of following periods:\n      Screening (within 28 days before study drug administration), inpatient period (Day 1 to 4)\n      and outpatient period (up to Day 141). Eligible participants will be randomly assigned in a\n      1:1 ratio to either 1 of 2 treatment groups (that is, Ustekinumab 90 mg/mL or Ustekinumab 5\n      mg/mL) and will receive treatment on Day 1. The PK comparability of 2 different formulations\n      of ustekinumab, diluted in saline, will be evaluated primarily. Participants' safety will be\n      monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a weight in the range of 50.0 kilogram (kg) to 90.0 kg, inclusive and a body\n             mass index (BMI) of 18.5 kilogram per square meter (kg/m^2) to 29.0 kg/m^2, inclusive\n\n          -  If a woman, she must be incapable of pregnancy or using a highly effective method of\n             birth control\n\n          -  A woman must have a negative serum pregnancy test\n\n          -  A man who is sexually active with a woman of childbearing potential and has not had a\n             vasectomy must agree to use a barrier method of birth control\n\n          -  Participant must be willing and able to adhere to the prohibitions and restrictions\n             specified in this protocol\n\n          -  Are nonsmokers or agree to smoke no more than 10 cigarettes or 2 cigars per day\n             throughout the study\n\n        Exclusion Criteria:\n\n          -  Participant currently has or has a history of any clinically significant medical\n             illness or medical disorders including malignancy\n\n          -  Participant has previously received ustekinumab\n\n          -  Participant has a known or suspected intolerance or hypersensitivity to any biologic\n             medication including ustekinumab\n\n          -  Participant has received an investigational drug within a specified period prior to\n             the planned first dose of study drug or is currently enrolled in an investigational\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156375", 
            "org_study_id": "CR104186", 
            "secondary_id": "CNTO1275NAP1002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ustekinumab 90 mg/mL", 
                "description": "Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.", 
                "intervention_name": "Ustekinumab", 
                "intervention_type": "Drug", 
                "other_name": "STELARA\u00ae"
            }, 
            {
                "arm_group_label": "Ustekinumab 5 mg/mL", 
                "description": "Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.", 
                "intervention_name": "Ustekinumab", 
                "intervention_type": "Drug", 
                "other_name": "STELARA\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Ustekinumab", 
            "STELARA\u00ae"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neptune", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open-label, Parallel-design Study to Compare Single-dose Pharmacokinetics of Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "This study is not yet recruiting patients. Please check back for future recruiting sites, or email"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The Cmax is the maximum observed plasma concentration of study drug.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 0 through Day 113"
            }, 
            {
                "description": "The AUC(0-inf) is the area under the serum concentration versus time curve from time zero to infinity with extrapolation of the terminal phase.", 
                "measure": "Area under the serum concentration versus time curve from time zero to infinity (AUC[0-inf])", 
                "safety_issue": "No", 
                "time_frame": "Day 0 through Day 113"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156375"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product and does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that meets any of the following conditions: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.", 
                "measure": "Number of participants with adverse events (AEs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 141"
            }, 
            {
                "description": "The AUC(0-last) is the area under the serum concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration.", 
                "measure": "Area under the serum concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration (AUC[0-last])", 
                "safety_issue": "No", 
                "time_frame": "Day 0 through Day 113"
            }, 
            {
                "description": "The T1/2 is the terminal half-life, that is, time required for the plasma concentration to decrease by one half.", 
                "measure": "Terminal half-life (T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 0 through Day 113"
            }, 
            {
                "description": "The CL is a quantitative measure of the rate at which a drug substance is removed from the body.", 
                "measure": "Total systemic clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Day 0 through Day 113"
            }, 
            {
                "description": "The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.", 
                "measure": "Volume of distribution (Vz)", 
                "safety_issue": "No", 
                "time_frame": "Day 0 through Day 113"
            }, 
            {
                "description": "Number of participants with antibodies to ustekinumab (tested using a validated immunoassay method) will be reported.", 
                "measure": "Number of participants with antibodies to ustekinumab", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Days 57 and 113"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}